Waist Circumference Measurements in Schizophrenic Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2010 by Changhua Christian Hospital.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Changhua Christian Hospital
ClinicalTrials.gov Identifier:
NCT01243034
First received: November 17, 2010
Last updated: NA
Last verified: October 2010
History: No changes posted
  Purpose

The prevalence of metabolic syndrome(MS) among pt's with schizophrenia has been reported to be high, ranging from 24 to 43% in males and 27 to 52% in females. Schizophrenic patients with MS have an increased incidence of DM, coronary heart disease and increased mortality from cardiovascular diseases. Central adiposity is highly correlated with the presence of hypertension, coronary heart disease, type 2 diabetes, and increased mortality risk. Waist circumference(WC) is a better indicator of abdominal obesity and a better predictor of CVD than either BMI or waist-to-hip ratio. However, currently there is no standard location for the measurement of WC.

Objectives: 1. To compare the magnitude of WC measured at 3 sites ( immediately above the iliac crest, midpoint between the lowest rib and the iliac crest , umbilical level) in males and females.

2. To examine the correlation of WC with Triglyceride, cholesterol, HDL, LDL and glucose.


Condition
Waist Circumference Measurements
Schizophrenia
Cardiovascular Risk Factor

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Variability of Waist Circumference Measurements at 3 Sites and Its Relationship With Cardiovascular Risk Factors in Patients With Schizophrenia

Resource links provided by NLM:


Further study details as provided by Changhua Christian Hospital:

Estimated Enrollment: 80
Study Start Date: November 2010
Estimated Study Completion Date: October 2011
Estimated Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

schizophrenia outpatients

Criteria

Inclusion Criteria:

  • • Patients with schizophrenia or schizoaffective disorder (DSM-IV 295) age 18 till 65 years old.

    • Body weight change less than 1 kg in previous one month before index date.

Exclusion Criteria:

  • • Patients with a previous hyperlipidemia diagnosis or antilipemic prescription during the preceding 30 days.

    • Patients received any anti-hypertensives or oral hypoglycemic agents.
    • Pregnant or breast-feeding women.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01243034

Locations
Taiwan
Changhua Christian Hospital
Changhua, Taiwan, 500
Sponsors and Collaborators
Changhua Christian Hospital
  More Information

No publications provided

Responsible Party: Cheng-Chen Chang, Changhua Christian Hospital
ClinicalTrials.gov Identifier: NCT01243034     History of Changes
Other Study ID Numbers: 100717
Study First Received: November 17, 2010
Last Updated: November 17, 2010
Health Authority: Taiwan: Department of Health

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders

ClinicalTrials.gov processed this record on April 16, 2014